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Background: Natural antioxidants in foods may be used in prevention and treatment of 
oxidative stress and inflammation in COPD. Therefore, this study aimed to evaluate the effect 
of conjugated linoleic acid (CLA) supplement as natural antioxidants on oxidative stress levels, 
and MMP2 and MMP9 serum levels in COPD patients.
Materials and methods: This clinical trial study was conducted on 90 (supplement 
group=45 and control group=45) COPD patients in Ardabil city, Iran, in 2015. After 
obtaining written consent, general information was collected from each patient using a 
validated and reliable questionnaire. Supplement group received 3.2 g of CLA and those in 
the control group were given 3.2 g of placebo for 6 weeks on a daily basis. Fasting blood 
samples were taken from all of the patients for testing of malondialdehyde (MDA), MMP2, 
and MMP9 levels at the beginning and end of the study. Data were analyzed using Kolm-
ogorov–Smirnov test, independent samples t-test, paired sample t-test, chi-square test, and 
ANOVA.
Results: There were no significant differences between the two groups with regard to mean 
age, smoking status, and serum level of MDA at the beginning of the study. In the supple-
ment group, the serum level of MDA decreased significantly at the end of the 6th week 
compared to that in the beginning of the study ( p=0.0004), while in the placebo group, 
the difference was found to be insignificant. The serum level of MMP9 decreased signifi-
cantly in the supplement group, while in the placebo group its level increased significantly 
as compared to that at the beginning of the study ( p,0.05). The serum levels of MMP2 
indicated no significant differences between the two groups neither at the beginning nor at 
the end of the study.
Conclusion: These findings indicated that CLA supplementation may be helpful for 
COPD patients through inhibiting the production of oxidative stress and controlling MMP9 
serum levels.
Keywords: COPD, CLA, oxidative stress, MMP2, MMP9
Introduction
COPD is the most prevalent chronic respiratory disease and one of the main causes 
of death throughout the world. It is characterized by progressive and irreversible 
airflow obstruction.1 From among the mechanisms involved in the pathogenesis of 
this disease, oxidative stress and inflammation have attracted increasing attention.2 
Oxidative stress is indicative of an increase in the production of various types of free 
radicals of oxygen from inflammatory cells and the inability of the biological system 
to detoxify them or repair their damaging effects, thus resulting in oxidative damage 
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to cells, tissues, and organs of the body.3 The increase of oxi-
dative stress in lungs causes an increase in the transcription 
of inflammatory genes, protease activity, mucus secretion, 
and resistance to glucocorticoid.4 An increase in the level of 
free radicals of oxygen leads to an augment, either directly 
or through lipid peroxidation products, in the inflammatory 
response, which has now been recognized as the main patho-
genic factor in the progression of COPD and the induction 
of matrix metalloproteinase (MMP) expressions.5 MMPs 
are a large family of protease enzymes, and 26 types have 
been recognized to date. It seems that MMPs have the most 
important role in the destruction and synthesis of collagen-
rich tissues in different physiological and pathological 
conditions.6 Among the enzymes in MMP family, the two 
enzymes of MMP2 (72 kDa gelatinase) and MMP9 (92 kDa 
gelatinase) have highest activity. MMP9 exists in low levels 
in the lung tissues of healthy humans. But, its level increases 
in severe pulmonary diseases such as asthma, primary pul-
monary fibrosis, COPD, and cystic fibrosis leading to an 
increase in disease severity and resistance to treatment.7–9 
In a study, an increase in the level of MMP2 was observed 
in the sputum samples taken from patients with asthma and 
COPD, which was statistically significant compared to the 
patients in control group.10 The destruction of the elasticity 
of the alveolar wall in COPD and its false reconstruction due 
to increased proteolytic activity result in the loss of alveolar 
function and disease progression. For this reason, MMPs 
have nowadays attracted increasing attention since they can 
have a potential role in the destruction and reconstruction 
of damaged alveoli.11 Regarding the role of oxidative stress 
in the pathogenesis of COPD, the use of antioxidant drugs 
as a new strategy for the treatment and prevention of this 
disease has become important.12 One of the supplements 
with antioxidant properties that has recently been focused on 
by many researchers due to its beneficial effects on human 
health condition is conjugated linoleic acid (CLA), which 
can be used together with usual treatments.12 CLA is a fatty 
acid with multiple double bonds which naturally exists in 
animal resources.13 The CLA supplements with different 
isomers can be used as antioxidant, anti-inflammatory, anti-
cancer, and anti-atherosclerosis substances; they can also 
be used as a stimulant of immune system and growth factor, 
for changing of body composition, and so on.14,15 Although 
a number of studies have demonstrated possible benefits of 
CLA intake on inflammatory factors,16,17 there is not enough 
evidence to establish positive effects of CLA consumption 
in reducing oxidative stress and inflammatory factors in the 
COPD subjects. There are no studies addressing the effect 
of CLA supplement on the levels of oxidative stress indices 
and serum levels of MMPs in COPD patients. Therefore, 
this study aimed to evaluate the effect of CLA supplement 
on the levels of oxidative stress, MMP2, and MMP9 in 
COPD patients.
Materials and methods
This study was a double-blind clinical trial which was con-
ducted on COPD patients in the Pulmonary Department at 
Imam Khomeini Hospital, Ardabil city, Iran, in 2015. At the 
beginning of the study, 168 male patients within the age range 
of 40–80 years were selected based on the criteria proposed 
by American Thoracic Society for having COPD, that is, 
coughing, phlegm production, and chronic dyspnea together 
with spirometry results with forced expiratory volume in first 
second (FEV
1
)/forced vital capacity (FVC)  ratio below 70%. 
Seventy-five patients, who were suffering from other chronic 
diseases such as cardiovascular diseases, diabetes, malignan-
cies, etc, were excluded. Three patients were excluded during 
the study due to lack of cooperation and abuse of CLA supple-
ments. Written informed consent form was obtained from 
each patient before the study. In order to collect the needed 
information about the patients such as their name, surname, 
age, education level, job, place of residence, smoking history 
and abandonment, and the number of exacerbations of disease 
during the previous year, a validated and reliable question-
naire was used for each patient. Finally, 90 patients (supple-
ment group=45 and control group=45) were evaluated. This 
research was ethically approved in the research department of 
Ardabil University of Medical Sciences (Iran) with the code of 
“Arums.REC.93.56” and recorded in the Clinical Trial Center 
of Iran with the code of IRCT2015080823559N1.
Supplementation
The patients in the supplement group received 3.2 g of CLA 
in softgel capsules (with 80% purity), which include c9-t11 
and c12-t10 isomers (50/50) and are manufactured in the 
form of tablets in the US with Nutrex research company the 
commercial name of Nutrex (Nutrex Reaserch Inc., Oviedo, 
FL, USA), while the control group received the same amount 
of placebo for 6 weeks. Before the beginning of the study, 
the containers of the CLA supplement and placebo were 
coded with letters A and B, respectively, to make sure that 
neither the interviewers nor the patients knew which group 
received which type of supplement, and therefore the process 
was double-blind.
Biochemical information
At the beginning of the study and at the end of the 6th week, 
3 mL of venous blood samples were taken from all of the 
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patients after 12 hours of fasting and gently transferred to 
test tubes. Then, the samples were labeled and transferred 
to the laboratory. After that, they were centrifuged for 
10 minutes at 4,000 rpm to separate the serum. Finally, the 
samples were distributed in four micro-tubes and kept at the 
temperature of -80°C for malondialdehyde (MDA), MMP2, 
and MMP9 tests.
The serum level of MDA was assessed by thiobarbituric 
acid reactive substances test using the reaction of thiobarbi-
turic acid. MDA is one of the oxidative stress biomarkers,18 
and it has been shown that there is an association between 
serum levels and COPD severity.19,20 The serum samples 
of patients were first heated with thiobarbituric acid under 
acidic conditions according to the instructions provided by 
the kit manufacturer and then cooled down. Afterward, the 
resulting color combination in n-butanol was extracted. 
The absorbance of the pink color was measured at 530 nm. 
Serum MMP2 and MMP9 levels were assayed by standard 
enzyme-linked immunosorbent assay (ELISA) kits (Boster, 
Wuhan, China). Serum samples were diluted 1:100 according 
to the manufacturer’s specifications for MMP9 and MMP2 
assay. For the accuracy of assessment, the experiments were 
performed in duplicate. The colors formed were read at the 
wavelengths of 450 and 630 nm by Anhos 2000 microplate 
reader, and the sample concentrations were calculated using 
Multcalc Software (Wallac, Turku, Finland).
Patients’ follow-up
In order to both control the consumption of supplementation 
and prevent the loss of samples, the follow-up was also done 
through face-to-face visits, in addition to making telephone 
calls. The pills needed for 6 weeks were given to the patients. 
They were asked to return the remaining pills if they stopped 
consuming them. In the following visits, 97% of the patients 
reported to have taken their pills regularly and were studied 
to find out the effects of the supplement on their disease. The 
compliance of patients in terms of taking their supplements 
was evaluated based on the number of remaining pills at the 
end of the 6th week of the study. The researcher provided the 
patients with some information about the possible complica-
tions of the supplement and gave them his phone number to 
contact him if they encountered any problem.
Data analysis and statistical methods
In order to check the normality of the data related to each 
variable, Kolmogorov–Smirnov test was employed. The 
information in the checklists was then transferred to SPSS 
Software (version 16), and in order to find the relationship 
between different variables, independent samples t-test, 
paired sample t-test, chi-square test, and ANOVA were 
performed. The significance level was taken to be 0.05 
for all the tests. The results were reported in the form of 
mean ± standard deviation.
Results
Demographic information and risk factors related to the 
patients and their comparison between the two groups 
are presented in Tables 1 and 2. Most of the patients in 
this study were urban residents. Most of the patients were 
farmers, and most of the subjects were illiterate. Based 
on the chi-square test, there was no significant difference 
with regard to variables (such as FEV
1
 percentage, age, 
Table 1 Demographic information of the COPD patients (n=90)
Variables Supplement group (n=45) Placebo group (n=45) p-value
Number Percentage Number Percentage
Job p.0.05 (nS)
employee 10 22.22 11 24.44
Farmer 20 44.22 15 33.33
Worker 5 11.11 4 8.88
Baker 2 4.44 2 4.44
Carpet weaver 1 2.22 1 2.22
Other 7 15.55 12 26.66
education level p.0.05 (nS)
Illiterate 20 44.44 18 40
less than a high school diploma 17 37.7 18 40
Diploma of high school 8 17.8 8 17.8
academic 0 0 1 2.2
Place of residence p.0.05 (nS)
Urban 35 77.7 33 73.3
rural 10 22.2 12 26.66
Abbreviation: NS, not significant.
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education level, occupational levels, smoking history and 
abandonment, and the number of exacerbations) between 
the two groups. The mean age of supplement and pla-
cebo groups was 63.60±10.94 (mean ± SD) years and 
61.64±10.60 years, respectively. The results indicated that 
there was no significant difference between the two groups 
regarding serum level of MDA at the beginning and end of 
the study. However, paired sample t-test revealed that the 
serum level of MDA decreased significantly at the end of 
the 6th week compared to that at the beginning of the study 
(p=0.0004) in the supplement group, while in the placebo 
group, the difference was found to be insignificant (p=0.3; 
Table 3). There were no significant differences in the serum 
levels of MMP2 between the two groups at the beginning 
and end of the study. The serum level of MMP2 decreased 
and increased insignificantly in supplement and placebo 
groups, respectively (Table 4). The results of the analysis 
of MMP9 levels revealed that at the beginning of the study, 
the two groups were not significantly different in this regard. 
However, the difference turned out to be significant at the 
end of the study (p,0.05). Paired sample t-test indicated 
that at the end of the 6th week, the serum level of MMP9 
decreased significantly in the supplement group, while in the 
placebo group, its level increased significantly as compared 
to the beginning of the study (p,0.05; Table 4).
Discussion
The results of this study indicated that CLA significantly 
decreased the serum levels of MDA and MMP9 in COPD 
patients at the end of the 6th week. In the placebo group, the 
serum levels of MMP9 increased significantly in patients. 
In the COPD patients, an increase in the level of oxidative 
stress has been observed, which might play a role in the 
pathogenesis of this disease.3 The increase of oxidative 
stress and different types of serum MMPs, especially MMP2 
and MMP9, has been reported as important factors in the 
pathogenesis of COPD in the patients suffering from this 
disease.3 In COPD, body cells are constantly exposed to 
various oxidizing agents. Reactive oxygen species (ROS) is 
one of the oxidizing compounds produced in human body.3,21 
On the other hand, analyses in laboratory conditions have 
shown that the increase of oxidative stress acts as a trigger 
for the increase of MMPs, especially MMP2 and MMP9.11 
Therefore, controlling oxidative stress and inhibiting the 
synthesis of MMPs are important in the treatment of this 
disease and can be considered as a new therapeutic strategy.22 
Although there are few studies about the effect of CLA on 
different cancers and some chronic diseases,15,23 very limited 
Table 2 risk factors related to the COPD patients and their comparison between the two groups
Variables Supplement group (n=45) Placebo group (n=45) p-value
Number Percentage Number Percentage
Having history of smoking cessation .0.05 (nS)
Positive 12 26.7 20 44.4
negative 33 73.3 25 55.6
Having history of baking bread .0.05 (nS)
Positive 2 4.44 1 2.22
negative 43 95.5 44 97.7
Having history of exacerbation .0.05 (nS)
Positive 25 55.5 24 53.3
negative 20 44.4 21 46.6
Abbreviation: NS, not significant.
Table 3 The average level of MDa in the supplement and control 
groups
Variables Measurement 
stage
Supplement 
group 
(n=45)
Placebo 
group 
(n=45)
p-value
MDa
(nmol/ml)
at the beginning
at the end
0.23±0.10
0.15±0.13
0.22±0.12
0.27±0.17
0.07
0.08
p-value 0.0004* 0.3
Notes: *p,0.05 in paired sample t-test vs baseline. The data are presented as 
mean ± SD.
Abbreviation: MDa, malondialdehyde.
Table 4 The average serum levels of MMP2 and MMP9 in the 
supplement and placebo groups
Variables Measurement 
stage
Supplement 
group 
(n=45)
Placebo 
group 
(n=45)
p-value
MMP2
(ng/ml)
at the beginning
at the end
986.27±108
980.33±100
996.27±75
1005±77
0.6
0.19
p-value 0.11 0.16
MMP9
(ng/ml)
at the beginning
at the end
827±113
735±104
849±149
875±135
0.4
0.00a
p-value 0.001b 0.001b
Notes: ap,0.05 in independent samples t-test between two groups; bp,0.05 in 
paired sample t-test vs baseline. The data are presented as mean ± SD.
Abbreviation: MMP, matrix metalloproteinase.
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investigations have been conducted about the effect of this 
supplement on COPD patients.
The results of this study are consistent with the find-
ings of the studies conducted by Baghi et al on healthy 
males,16 Hassan Eftekhari et al on cardiovascular patients,24 
and Aryaeian et al on patients with rheumatoid arthritis.25 
In their studies, they indicated that the consumption of CLA 
supplement can decrease the serum level of MDA, which 
is an index of oxidative stress. The reason for the decrease 
in the serum level of MDA might be the anti-inflammatory 
effect of CLA as the result of the activation of peroxisome 
proliferator-activated receptors. Through this process, CLA 
finally leads to the inhibition of some key factors involved 
in the induction of oxidative stress and triggers the produc-
tion of some proinflammatory factors.26–28 During the present 
study, the serum level of MDA significantly decreased in 
the supplement group, while in the placebo group, its level 
slightly increased. Antioxidant enzymes and compounds 
are produced in the body to cope with oxidative stress 
conditions21 so as to protect the cells and living tissues of 
the body against the damages caused by free radicals and 
ROS.3 Therefore, treatment with nutritional antioxidants 
might be helpful. In other study, Shadman et al found that 
the consumption of CLA did not change the serum level of 
MDA significantly in patients with type II diabetes.29 Their 
finding is inconsistent with the results of our study, the 
possible reasons for which might be the different statistical 
populations addressed in each study and the increase of 
resistance to insulin and peroxidation lipids as the result of 
CLA consumption in patients with diabetes.29
In the present study, the serum concentration of MMP9 
significantly decreased in COPD patients after the consump-
tion of CLA, which shows the positive effect of this supple-
ment. Our results are in line with the findings of the studies 
conducted by Hubbard et al,30 Harris et al,31 and Soel et al,32 
who found that the consumption of CLA can decrease 
the serum level of MMP9 in healthy and cancerous rats. 
Although the exact mechanism of action of CLA on MMP2 
and MMP9 in COPD patients is unknown, some research-
ers have reported that it can affect the gene expression of 
MMP2 and MMP9 and suppress their activity via stopping 
the production of mRNAs.30 An evidence for this explana-
tion can come from the study of Hubbard et al in which 
they observed the destruction of mRNAs of these MMPs in 
rats.30 Another mechanism may be related to the regulation 
of gene expression of MMPs by cytokines.22 Probably, the 
consumption of CLA decreases the production of MMPs via 
the inhibition of cytokines.33 Finally, the third mechanism of 
action is the decrease in the production of oxidative stress 
considering the fact that MMPs alone are inactive and it 
is the oxidative stress that activates them.6 Platt et al have 
shown34 that the CLA did not affect the level of MMP9, 
which is inconsistent with our findings. This inconsistency 
might be due to the different settings in which the study 
has been conducted and also the individual differences of 
the patients under study, such as age, gender, and having 
other diseases, and the duration of the intervention should 
also be considered.11
The duration of intervention and assessment of CLA 
blood levels in the patients were the main limitations of 
this study.
Conclusion
The serum levels of MDA and MMP9 decreased signifi-
cantly, and an insignificant decrease in the serum level of 
MMP2 at the end of the 6th week after CLA supplemen-
tation was observed. These findings indicated that CLA 
supplementation may be helpful for COPD patients through 
inhibiting the production of oxidative stress and controlling 
MMP9 serum levels.
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